Results 161 to 170 of about 1,807,537 (411)

Predicting Prostate Cancer Aggressiveness through a Nanoparticle Test [PDF]

open access: yes, 2011
Prostate cancer (PCa) is the most common malignancy and the second leading cause of cancer death in American men. Due to the lack of accurate tests to distinguish aggressive cancer from indolent tumor, prostate cancer is often over-treated.
David Decker   +5 more
core   +1 more source

Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up [PDF]

open access: yes, 2012
<b>Background</b> High cholesterol may be a modifiable risk factor for prostate cancer but results have been inconsistent and subject to potential "reverse causality" where undetected disease modifies cholesterol prior to diagnosis.<p ...
A Jemal   +48 more
core   +2 more sources

Xanthogranulomatous Prostatitis, a Rare Prostatic Entity

open access: yesUrology Case Reports, 2017
There are several benign prostatic pathologies that can clinically mimic a prostate adenocarcinoma. Xanthogranulomatous prostatitis is a benign inflammatory condition of the prostate and a rare entity. A 47-year old male, with 3 years of lower urinary tract symptoms, with a palpable hypogastric tumor, digital rectal examination: solid prostate, of ...
Omar Piñon   +8 more
openaire   +3 more sources

Thermal proteome profiling and proteome analysis using high‐definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next‐generation galeterone analog VNPP433‐3β in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Elevated level of cholesterol is positively correlated to prostate cancer development and disease severity. Cholesterol‐lowering drugs, such as statins, are demonstrated to inhibit prostate cancer. VNPP433‐3β interrupts multiple signaling and metabolic pathways, including cholesterol biosynthesis, AR‐mediated transcription of several oncogenes, mRNA 5′
Retheesh S. Thankan   +10 more
wiley   +1 more source

A feasible roadmap for developing volumetric probability atlas of localized prostate cancer [PDF]

open access: yesarXiv, 2014
A statistical volumetric model, showing the probability map of localized prostate cancer within the host anatomical structure, has been developed from 90 optically-imaged surgical specimens. This master model permits an accurate characterization of prostate cancer distribution patterns and an atlas-informed biopsy sampling strategy.
arxiv  

Germline variants in CDKN2A wild‐type melanoma prone families

open access: yesMolecular Oncology, EarlyView.
Among melanoma‐prone families, wild‐type for CDKN2A and CDK4, some have pathogenic variants in genes not usually linked to melanoma. Furthermore, rare XP‐related variants and variants in MC1R are enriched in such families. Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic
Gjertrud T. Iversen   +5 more
wiley   +1 more source

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

open access: yesNew England Journal of Medicine, 2004
BACKGROUND The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or ...
I. Thompson   +11 more
semanticscholar   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

open access: yesMolecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau   +11 more
wiley   +1 more source

Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. [PDF]

open access: yes, 2019
Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations
Aldahl, Joseph   +14 more
core  

Home - About - Disclaimer - Privacy